Skip to main content

Table 1 Patient and treatment characteristics

From: Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma

Parameter Nr
A. Patient and tumor characteristics
Age (years) Median (range) 67 (36-87)
Gender
 Male 24 (56%)
 Female 19 (44%)
Tumor location a
 IHCC 17 (40%)
 EHCC 26 (60%)
Treatment
 Primary inoperable 26 (70%)
 Recurrent 8 (22%)
 Positive margins 3 (08%)
Prior therapies
 Resection 12 (32%)
 Chemotherapy 6 (16%)
  Gemcitabine/Oxaliplatin 1
  Gemcitabine 1
  Capecitabin 1
  5-FU 1
Therapies after SBRT
 Chemotherapy 13 (35%)
 TACE 1 (03%)
CA 19-9 (U/ml) Median (IQR) 149 (20-499)
Bilirubin (mg/dl) Median (range) 0.8 (0.5-21)
GTV Diameter (cm)a Median (IQR) 4.9 (3.4-8.2)
PTV Volume (cm3)a Median (IQR) 124 (60-329)
B. Treatment characteristics
Prescribed dose (Gy)a
 Median (IQR) 45 (38-48)
 Maximum point dose (Gy)a
 Median (IQR) 51 (44-58)
 Mean PTV dose (Gy)a
 Median (IQR) 47 (42-51)
 EQD210 (Gy)a
 Median (IQR) 56 (47-61)
EQD210 Maximum point dose (Gy)
 Median (IQR) 65 (59-85)
EQD210 Mean dose (Gy)
 Median (IQR) 63 (53-82)
  1. IHCC Intrahepatic cholangiocarcinoma, EHCC Extrahepatic cholangiocarcinoma, 5-FU 5-Fluoruracil, IQR interquartile range, EQD2 equieffective doses in 2 Gy (α/β = 10)
  2. aper lesion